↓ Skip to main content

Regulatory Aspects of Gene Therapy and Cell Therapy Products

Overview of attention for book
Attention for Chapter 9: Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy
2 policy sources

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea
Chapter number 9
Book title
Regulatory Aspects of Gene Therapy and Cell Therapy Products
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-3-319-18618-4_9
Pubmed ID
Book ISBNs
978-3-31-918617-7, 978-3-31-918618-4
Authors

Minjoung Choi, Euiri Han, Sunmi Lee, Taegyun Kim, Won Shin, Choi, Minjoung, Han, Euiri, Lee, Sunmi, Kim, Taegyun, Shin, Won

Abstract

The Ministry of Food and Drug Safety regulates gene therapy and cell therapy products as biological products under the authority of the Pharmaceutical Affairs Act. As with other medicinal products, gene therapy and cell therapy products are subject to approval for use in clinical trials and for a subsequent marketing authorization and to post-market surveillance. Research and development of gene therapy and cell therapy products have been progressing rapidly in Korea with extensive investment, offering great potential for the treatment of various serious diseases. To facilitate development of safe and effective products and provide more opportunities to patients suffering from severe diseases, several regulatory programs, such as the use of investigational products for emergency situations, fast-track approval, prereview of application packages, and intensive regulatory consultation, can be applied to these products. The regulatory approach for these innovative products is case by case and founded on science-based review that is flexible and balances the risks and benefits.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 20%
Student > Ph. D. Student 4 16%
Student > Doctoral Student 3 12%
Researcher 2 8%
Other 1 4%
Other 4 16%
Unknown 6 24%
Readers by discipline Count As %
Medicine and Dentistry 7 28%
Biochemistry, Genetics and Molecular Biology 5 20%
Engineering 2 8%
Agricultural and Biological Sciences 2 8%
Business, Management and Accounting 1 4%
Other 2 8%
Unknown 6 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2023.
All research outputs
#5,402,691
of 25,287,709 outputs
Outputs from Advances in experimental medicine and biology
#909
of 5,279 outputs
Outputs of similar age
#71,328
of 364,989 outputs
Outputs of similar age from Advances in experimental medicine and biology
#46
of 274 outputs
Altmetric has tracked 25,287,709 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,279 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 274 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.